Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Informative Articles About Novocure (Medical Device/Cancer  Treatment Company)

|About: NovoCure Limited (NVCR)
Summary

Novocure is a company that uses Tumor Treating Fields to treat cancer.

Optune, one of the Novocure's products, is FDA-approved for treating recurrent glioblastoma and newly diagnosed glioblastoma. (www.novocure.com).

There are also clinical trials using Tumor Treating Fields for other types of cancer. (https://www.novocuretrial.com/).

Novocure's stock has increased ~107% YTD.(https://money.cnn.com/quote/quote.html?symb=NVCR).

Novocure is a stock that is worth investigating further. Here are some interesting and useful articles about the company:

https://www.barrons.com/articles/how-to-invest-in-health-care-stocks-under-the-shadow-of-medicare-for-all-51563467481 

https://www.fool.com/investing/2019/07/03/why-novocure-stock-jumped-19-in-june.aspx

https://finance.yahoo.com/news/5-key-takeaways-novocure-apos-143839350.html

Novocure's growth prospects and the data that has become available so far are appealing; however, although the author is not an expert in this area, Optune as a product may perhaps pose a technological risk due to its new and novel nature. I appreciate any comments and I hope to conduct a deeper analysis of this stock soon.  

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Additional disclosure: Welcome. In the content published by the author on Seeking Alpha, stocks, bonds, and other investment ideas are discussed. Nothing in this site is intended to serve as or consists of financial, legal, investment, or tax advice. The author is not an investment or financial adviser. No content on this site constitutes financial or investment advice, a formal recommendation to buy, sell or hold a security, financial instrument or other investment product, or a solicitation of investment. Many of the statements made are forward-looking statements which are subject to risk and uncertainty. All investments are subject to risk. You agree that the author does not have any responsibility or liability for any loss – monetary or otherwise – or any adverse effect that results from any decisions made by any reader or user of this content. The information presented in this article has been obtained from sources that the author believes are reliable, but the author does not guarantee that this information is accurate and complete. All content is provided “as-is”, and without any warranties or guarantees, either express or implied. Please do your own diligence and make your own decisions regarding any investment or financial matter. You agree that any investment or other decision that you make in regard to, or in reliance on any of the information and content provided by this author is made solely at your own risk.

All inclusions of content from third parties, or that is created by others, are done in the good-faith belief that the author is making fair use of this content. In the absence of being contacted and told otherwise, the author will conclude that he is utilizing your content in an appropriate and lawful manner.

You agree to indemnify, defend, and hold harmless the author of this content for any losses or damages relating to or arising out of your use of this content. To the maximum extent permitted by law, in no event shall the author of this content be liable for any damages whatsoever resulting from, arising out of, or in any way connected with this content, or the use thereof.

The disclosure regarding stocks that the author owns or will purchase in the next 72 hours is based only on what the author knows to the best of the author's knowledge. This disclosure applies only to stocks, bonds, or other investment products that the author buys and sells in his individual account. This disclosure does not apply to stocks, bonds, or other investment products that are purchased, owned, or sold by mutual funds, managed funds, index funds, Investment Retirement Accounts, accounts managed by others, or other similar products that are owned by the author as part of his portfolio.

Please feel free to contact that author with any questions or comments. The author thanks you for your time in reading his work.